NCT05256225

NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA

Icon for trial | NRG GY026 NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL S

This study is currently enrolling.

This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer quest ...

NCT05147220

A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib

Icon for trial | CLOU064C12302 A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrut

This study is currently enrolling.

The main purpose of the study is to find out if patients treated with remibrutinib may experience fewer MS relapses (also called clinical attacks, exacerbations or flare ups) than patients treated with teriflunomide (also known ...

NCT05766813

“A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson’s Disease”

Icon for trial | ITI-214-202 “A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson’s Disease”

This study is currently enrolling.

The purpose of this clinical research study is to look at an investigational study drug called lenrispodun. The study will investigate if lenrispodun can help to increase the time of good control of movement symptoms, that is, ...

NCT05610163

THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

Icon for trial | A022104 THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

This study is currently enrolling.

To evaluate and compare the cCR rates in patients with locally advanced rectal cancer treated with neoadjuvant LCRT followed by neoadjuvant mFOLFIRINOX versus neoadjuvant LCRT followed by neoadjuvant mFOLFOX6.To evaluate and co ...

NCT03000439

You are being asked to take part in this research study because you have Systemic Juvenile Idiopathic Arthritis (sJIA) which may cause joint swelling and pain, fever, or other symptoms affecting the whole body (such as rash, swelling of your lymph nodes, a large liver or spleen, or inflammation of the lining around your lungs or heart). The purpose of this research study is to compare the effectiveness of the study drug, tofacitinib, to placebo for treatment of signs and symptoms of sJIA.

Icon for trial | A3921165 You are being asked to take part in this research study because you have Systemic Juvenile Idiopathic Arthritis (sJIA) which may cause joint swelling and pain, fever, or other symptoms affecting the whole body (such as rash, swelling of your lymp

You are being asked to take part in this research study because you have Systemic Juvenile Idiopathic Arthritis (sJIA) which may cause joint swelling and pain, fever, or other symptoms affecting the whole body (such as rash, sw ...

Subscribe to